[go: up one dir, main page]

WO1999040113A3 - Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques - Google Patents

Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques Download PDF

Info

Publication number
WO1999040113A3
WO1999040113A3 PCT/FR1999/000259 FR9900259W WO9940113A3 WO 1999040113 A3 WO1999040113 A3 WO 1999040113A3 FR 9900259 W FR9900259 W FR 9900259W WO 9940113 A3 WO9940113 A3 WO 9940113A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
concerns
lipopeptide
amino acids
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1999/000259
Other languages
English (en)
Other versions
WO1999040113A9 (fr
WO1999040113A2 (fr
Inventor
Kader Thiam
Claude Auriault
Helene Gras-Masse
Estelle Loing
Claudie Verwaerde
Jean Gerard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9522697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999040113(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU22842/99A priority Critical patent/AU2284299A/en
Priority to JP2000530541A priority patent/JP2002506003A/ja
Priority to EP99902607A priority patent/EP1054901A2/fr
Priority to US09/601,729 priority patent/US6683052B1/en
Publication of WO1999040113A2 publication Critical patent/WO1999040113A2/fr
Publication of WO1999040113A9 publication Critical patent/WO1999040113A9/fr
Publication of WO1999040113A3 publication Critical patent/WO1999040113A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne tout lipopeptide caractérisé en ce qu'il comprend: une partie peptidique comprenant la séquence peptidique constituée par environ 30 à environ 50 des derniers acides aminés contigus de l'extrémité C-terminale de l'interféron-η (IFN-η) des mammifères, dont, le cas échéant, les 3 à 20 derniers acides aminés ont été supprimés; et une ou plusieurs parties lipophiles comprenant une chaîne hydrocarbonée en C4 à C20, saturée ou insaturée, linéaire ou ramifiée, ou un groupe stéroïde. L'invention concerne également tout lipopeptide tel que défini ci-dessus, contenant un ou plusieurs épitopes CD8, et/ou CD4, et/ou B. L'invention a également pour objet les médicaments ou vaccins contenant tout lipopeptide tel que défini ci-dessus.
PCT/FR1999/000259 1998-02-06 1999-02-05 Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques Ceased WO1999040113A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU22842/99A AU2284299A (en) 1998-02-06 1999-02-05 Lipopeptides containing an interferon fragment and uses thereof in pharmaceutical compositions
JP2000530541A JP2002506003A (ja) 1998-02-06 1999-02-05 インターフェロン−γフラグメントを含むリポペプチド、及び薬学的組成物におけるその使用
EP99902607A EP1054901A2 (fr) 1998-02-06 1999-02-05 Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques
US09/601,729 US6683052B1 (en) 1998-02-06 1999-02-05 Lipopeptides containing an interferon-γ fragment, and uses thereof in pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR98/01439 1998-02-06
FR9801439A FR2774687B1 (fr) 1998-02-06 1998-02-06 Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques

Publications (3)

Publication Number Publication Date
WO1999040113A2 WO1999040113A2 (fr) 1999-08-12
WO1999040113A9 WO1999040113A9 (fr) 1999-10-21
WO1999040113A3 true WO1999040113A3 (fr) 2000-04-06

Family

ID=9522697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/000259 Ceased WO1999040113A2 (fr) 1998-02-06 1999-02-05 Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques

Country Status (6)

Country Link
US (1) US6683052B1 (fr)
EP (1) EP1054901A2 (fr)
JP (1) JP2002506003A (fr)
AU (1) AU2284299A (fr)
FR (1) FR2774687B1 (fr)
WO (1) WO1999040113A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
ATE343375T1 (de) * 2001-03-27 2006-11-15 Biomira Inc Impfstoff zur modulation zwischen t1 und t2 immunantworten
ATE529123T1 (de) * 2002-04-15 2011-11-15 Oncothyreon Inc Synthetische glykolipopeptide als impfstoffe
WO2005037261A1 (fr) * 2003-10-14 2005-04-28 Biomira, Inc. Polytherapie du cancer
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
CA2607806A1 (fr) * 2005-05-04 2006-11-16 Nautilus Biotech, S.A. Polypeptides d'interferon-gamma modifies et procedes d'utilisation de polypeptides d'interferon-gamma modifies
HUE026490T2 (en) 2005-06-28 2016-06-28 Oncothyreon Inc A method of treating patients with a mucin glycoprotein (MUC-1) vaccine
AU2007305268A1 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the C2 domain of epsilon PKC, and use thereof
WO2010151495A2 (fr) * 2009-06-26 2010-12-29 University Of Florida Research Foundation Inc. Matériaux et procédés pour traiter et prévenir des infections virales
BR112012012406B1 (pt) 2009-11-23 2021-11-16 Cubist Pharmaceuticals Llc Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação
CN103014015B (zh) * 2010-03-26 2014-09-10 华南农业大学 编码猪γ干扰素的基因片段及其应用
US9475839B2 (en) 2010-05-11 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
CN103781469B (zh) 2011-02-24 2015-09-16 肿瘤防护公司 含有佐剂的以muc1为基础的糖脂肽疫苗
US9878054B2 (en) * 2012-05-18 2018-01-30 Tufts Medical Center, Inc. Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereto
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
FR3091651A1 (fr) 2019-01-11 2020-07-17 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre
FR3096894A1 (fr) 2019-06-06 2020-12-11 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8 immunogènes du virus ebola
CN117024563B (zh) * 2023-06-16 2024-04-19 苏州西山生物技术有限公司 分泌实验猴γ-干扰素单克隆抗体的杂交瘤细胞及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236987A2 (fr) * 1986-03-10 1987-09-16 F. Hoffmann-La Roche Ag Protéines chimiquement modifiées et leur production
EP0510356A1 (fr) * 1991-03-25 1992-10-28 F. Hoffmann-La Roche Ag Conjugués polyéthylène glycol-protéine
US5270038A (en) * 1992-01-23 1993-12-14 Board Of Regents, The University Of Texas System Tumor necrosis factor receptors on microorganisms
EP0593868A1 (fr) * 1992-08-26 1994-04-27 F. Hoffmann-La Roche Ag Conjugués PEG-interféron
WO1997018832A1 (fr) * 1995-11-21 1997-05-29 Enzon, Inc. Conjugues de polymere et d'interferon et processus de preparation de ces conjugues

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236987A2 (fr) * 1986-03-10 1987-09-16 F. Hoffmann-La Roche Ag Protéines chimiquement modifiées et leur production
EP0510356A1 (fr) * 1991-03-25 1992-10-28 F. Hoffmann-La Roche Ag Conjugués polyéthylène glycol-protéine
US5270038A (en) * 1992-01-23 1993-12-14 Board Of Regents, The University Of Texas System Tumor necrosis factor receptors on microorganisms
EP0593868A1 (fr) * 1992-08-26 1994-04-27 F. Hoffmann-La Roche Ag Conjugués PEG-interféron
WO1997018832A1 (fr) * 1995-11-21 1997-05-29 Enzon, Inc. Conjugues de polymere et d'interferon et processus de preparation de ces conjugues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEPREZ B. ET AL.: "Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus specific CTL", VACCINE, vol. 14, no. 5, 1996, UK, pages 375 - 382, XP004057291 *
ROUAIX F. ET AL.: "Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells", VACCINE, vol. 12/13, 1994, GB, pages 1209 - 1214, XP002082968 *
THIAM K. ET AL.: "Unrestricted agonist activity on murine and human cells of a lipopeptide derived from IFN-gamma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 253, no. 3, 30 December 1998 (1998-12-30), pages 639 - 647, XP002102358 *

Also Published As

Publication number Publication date
JP2002506003A (ja) 2002-02-26
FR2774687A1 (fr) 1999-08-13
EP1054901A2 (fr) 2000-11-29
WO1999040113A9 (fr) 1999-10-21
FR2774687B1 (fr) 2002-03-22
US6683052B1 (en) 2004-01-27
AU2284299A (en) 1999-08-23
WO1999040113A2 (fr) 1999-08-12

Similar Documents

Publication Publication Date Title
WO1999040113A3 (fr) Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
EP1440980A3 (fr) Analogues peptidiques de la protéine basique de la myéline humaine
ATE368053T1 (de) Antimikrobielle peptide
IL142350A0 (en) Interferon-beta fusion proteins and pharmaceutical compositions containing the same
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE68916932D1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
BR0205983A (pt) fármacos peptìdicos antiangiogênicos
AU5376201A (en) Methods and compositions for impairing multiplication of hiv-1
HUT62916A (en) Process for producing immunogenic peptides and pharmaceutical compositions comprising same
WO1996028470A3 (fr) Analogues peptidiques de proteine de base de myeline utile dans le traitement de la sclerose en plaques
BR0308860A (pt) Fator viii modificado
BR9306272A (pt) Peptídeo e composiçao farmacêutica
EP0733071A4 (fr) Antagonistes de la chaperonine 10
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
WO1993019178A3 (fr) Peptides utilises pour l'induction de tolerance
EP0770624A3 (fr) Peptide pouvant induire une réponse immune contre le cancer de l'estomac et agent contenant ce peptide pour la prévention ou le traitement du cancer de l'estomac
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
ATE356140T1 (de) Gd3 mimetische peptide
SG142165A1 (en) Biologically active peptides
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
NZ508812A (en) Peptides for the prevention or treatment of HIV
MXPA05004849A (es) Novedosas composiciones de multiples peptidos antigenicos relacionados con inhibina, que mejoran el desempeno de produccion avicola.
IL141996A0 (en) Moraxella catarrhalis basb034 polypeptides and uses thereof
EP0717752A4 (fr) Composes therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 9-12, 21 AND 22, DESCRIPTION, REPLACED BY NEW PAGES 9-12, 21 AND 22; PAGES 60 AND 61, CLAIMS,REPLACED BY NEW PAGES 60 AND 61; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999902607

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 22842/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09601729

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999902607

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999902607

Country of ref document: EP